The chief executive of dual-listed healthcare product company Ebos is confident in continued growth even as it faces the loss of a $2 billion contract next year and in the face of an uncertain macroeconomic environment.
Ebos yesterday reported revenue for the year ended June 30 up 14% to $12.2
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
